The earnings call highlighted significant advancements towards clinical trials and strong community support, but these were overshadowed by financial challenges, NASDAQ delisting, and funding uncertainties. The sentiment is balanced between optimism for future trials and concern over current financial hurdles.

Company Guidance

During the Brainstorm Cell Therapeutics Second Quarter 2025 Conference Call, the company emphasized its commitment to advancing the NurOwn platform for ALS treatment through a planned Phase IIIb trial called ENDURANCE, following FDA clearance in May. The trial's design has been agreed upon with the FDA under a Special Protocol Assessment (SPA), aiming to support a future Biologics License Application (BLA). Financially, Brainstorm reported R&D expenditures of $1.1 million for the quarter ending June 30, 2025, up from $0.9 million in 2024, and a net loss of $2.9 million compared to $2.5 million the previous year. The company is actively seeking funding to initiate the trial and regain NASDAQ compliance, following a transition to the OTCQB. Additionally, a Citizens Petition has been filed with the FDA by ALS patients and families, advocating for a de novo review of NurOwn's data, which includes promising five-year survival statistics from an expanded access program.

FDA Clearance for Phase IIIb Trial

Brainstorm Cell Therapeutics received FDA clearance to initiate a pivotal Phase IIIb trial, ENDURANCE, for NurOwn in early-stage ALS patients. This provides regulatory clarity and strengthens the trial's foundation.

Manufacturing Partnership with Minaris

Secured a partnership with Minaris Advanced Therapies to enhance U.S.-based manufacturing capabilities for the upcoming clinical trial.

Support from ALS Community

A citizens petition was filed with the FDA by ALS patients and families, requesting a de novo review of NurOwn's data, showcasing strong community support.

Brainstorm Cell Therapeutics (BCLI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BCLI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.37 / -	-0.51	―	―	―
Aug 14, 2025	2025 (Q2)	-0.37 / -0.34	0.6	-156.67% (-0.94)	―
May 16, 2025	2025 (Q1)	- / -0.45	-0.75	40.00% (+0.30)	―
Mar 31, 2025	2024 (Q4)	-0.97 / -0.45	-0.75	40.00% (+0.30)	―
Nov 14, 2024	2024 (Q3)	-0.57 / -0.51	-0.45	-13.33% (-0.06)	―	―
Aug 14, 2024	2024 (Q2)	-0.53 / 0.60	-1.95	130.77% (+2.55)	―
May 14, 2024	2024 (Q1)	- / -	-0.14	―	―	―
Apr 01, 2024	2023 (Q4)	-1.05 / -0.75	-2.1	64.29% (+1.35)	―	―
Nov 14, 2023	2023 (Q3)	-2.25 / -0.45	-2.85	84.21% (+2.40)	―
Aug 14, 2023	2023 (Q2)	-2.17 / -1.95	-2.85	31.58% (+0.90)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BCLI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$0.66	$0.60	-9.09%
May 16, 2025	$1.16	$1.32	+13.79%
Mar 31, 2025	$1.19	$1.26	+5.88%
Nov 14, 2024	$1.13	$1.21	+7.08%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Brainstorm Cell Therapeutics (BCLI) report earnings?

Brainstorm Cell Therapeutics (BCLI) is schdueled to report earning on Nov 17, 2025, Before Open (Confirmed).

What is Brainstorm Cell Therapeutics (BCLI) earnings time?

Brainstorm Cell Therapeutics (BCLI) earnings time is at Nov 17, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BCLI EPS forecast?

BCLI EPS forecast for the fiscal quarter 2025 (Q3) is -0.37.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing